Compare KRNT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | ABUS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 839.5M |
| IPO Year | 2014 | 2008 |
| Metric | KRNT | ABUS |
|---|---|---|
| Price | $17.99 | $4.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $19.75 | $5.00 |
| AVG Volume (30 Days) | 304.9K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $4.52 | N/A |
| Revenue Next Year | $7.84 | $239.71 |
| P/E Ratio | ★ N/A | $5.45 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $11.93 | $3.35 |
| 52 Week High | $19.78 | $5.38 |
| Indicator | KRNT | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 69.68 | 56.21 |
| Support Level | $13.97 | $4.11 |
| Resistance Level | $19.78 | $4.82 |
| Average True Range (ATR) | 0.75 | 0.15 |
| MACD | 0.25 | 0.03 |
| Stochastic Oscillator | 73.15 | 92.39 |
Kornit Digital Ltd is a developer and provider of digital solutions for the printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value-added services that enable large-scale printing of short-run complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink, and other consumables, and services, including software subscriptions. The company geographically operates in the U.S., EMEA, Asia Pacific, and other countries. It derives maximum revenue from the U.S.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.